Ingrezza treatment eases disease burden due to Huntington’s chorea
Daily treatment with Ingrezza (valbenazine) led to reductions in motor- and cognitive-related disease burden for adults with chorea due to Huntington’s disease, according to new data analyses from the Phase 3 KINECT-HD clinical trial. These changes were assessed with a relatively new patient-reported measure, called the Huntington’s Disease…